Activating mutations in NRAS (usually at codons Q60/61 and G12/13) are detected in approximately 20% of melanomas, which can result in activation of various pathways, including the RAS/RAF/MEK/ERK, protein kinase C (PKC), and PI3K/AKT pathways [35,36]. The gene discussed is MAP2K7; the disease is melanoma.